Role of [18F]FDG PET/CT in patients with no special type breast cancer: Literature review and comparison between guidelines
-
Published:2024-09
Issue:
Volume:
Page:103806
-
ISSN:0960-9776
-
Container-title:The Breast
-
language:en
-
Short-container-title:The Breast
Author:
Groheux DavidORCID,
Vaz Sofia C.,
Poortmans Philip,
Mann Ritse M.,
Ulaner Gary A.,
Cook Gary J.R.,
Hindié Elif,
Pilkington Woll John Patrick,
Jacene Heather,
Rubio Isabel T.,
Vrancken Peetersr Marie-Jeanne,
Dibble Elizabeth H.,
de Geus-Oei Lioe-Fee,
Graff Stephanie L.,
Cardoso Fatima
Reference159 articles.
1. Current and future burden of breast cancer: Global statistics for 2020 and 2040;Arnold;Breast,2022
2. Biomarker expression and St Gallen molecular subtype classification in primary tumours, synchronous lymph node metastases and asynchronous relapses in primary breast cancer patients with 10 years’ follow-up;Falck;Breast Cancer Res Treat,2013
3. Joint EANM-SNMMI guideline on the role of 2-[18F]FDG PET/CT in no special type breast cancer : (endorsed by the ACR, ESSO, ESTRO, EUSOBI/ESR, and EUSOMA);Vaz;Eur J Nucl Med Mol Imaging,2024
4. Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations;Avril;J Clin Oncol,2000
5. Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography;Bos;J Clin Oncol,2002